Imatinib (STI571, Gleevac) as Initial Therapy for Patients with Newly Diagnosed Ph + Chronic Myeloid Leukemia (CML): Results of a Randomized Phase III Study vs Interferon-Alpha + Cytarabine (IFN + AraC)

Reviewer: Ryan Smith, MD
Ultima Vez Modificado: 8 de diciembre del 2002

Translation for this article does not exist


7 Tips for Giving Smart on #givingtuesday
by Christina Bach, MSW, LCSW, OSW-C
November 25, 2015